Serum miRNA-204-5p as a potential noninvasive biomarker for the diagnosis of endometrial cancer with sentinel lymph node mapping

Cailiang Wu,Xuexin Zhou,Jiayong Li,Ruiying Xiao,Ye Yang,Haomin Xin,Lei Dai,Yaping Zhu,Sufang Wu,Wei Bao

DOI: https://doi.org/10.21203/rs.3.rs-403149/v1

2021-01-01

Abstract:Abstract Background Lymph node status is one of the most important prognosis factors in determining adjuvant treatment in endometrial cancer (EC). However, lymphadenectomy bears significant surgical and postoperative risks. The use of the sentinel lymph node mapping (SLNM) has emerged as an alternative method to complete lymphadenectomy in EC. There remains controversy surrounding the SLNM in high-risk disease and its false negative rate (3%). We previously identified miR-204-5p is tumor suppressor miRNA associated with lymph node metastasis in endometrial cancer tissues. Here, we report serum miR-204-5p in EC patients have potential early diagnostic value combined with sentinel lymph node mapping. Methods The relative expression levels of miR-204-5p were detected by quantitative RT-PCR in the serum of 52 EC patients (total SLNM), 20 benign ovarian cyst patients and 20 myoma patients. The miR-204-5p expression was also detected in endometrial cancer tissues by in situ hybridization. Results Our results showed that serum miR-204-5p expression was down-regulated in EC patients than that in the benign ovarian cyst or myoma patients (p < 0.01).In accordance with final pathological evaluation, positive SLN EC patients have a significant lower level of miR-204-5p compared with negative SLN EC patients. The area under the ROC curve of miR-204-5p was 0.923, 95% CI(0.847, 1.000), and the diagnostic value with a sensitivity of 87.2% specificity of 80.0%. Conclusions Lower miR-204-5p expression is associated with lymph node metastasis in these SLN(+) EC tissues, indicate that down-regulation of serum miR-204-5p in EC patients have potential early diagnostic value combined with sentinel lymph node mapping.